🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Meet Rishi Mehta, one of our talented scientists at Palleon! Whether he’s in the lab or playing giant Jenga at a team event, Rishi knows that success comes from great teammates and a shared vision. We asked him about our culture and mission to treat disease through #glycobiology.

March is #AutoimmuneAwarenessMonth! At Palleon, we believe #glycobiology can transform autoimmune treatment. E-602, our lead candidate, depletes activated memory B cells—the key drivers of disease—efficiently. Learn more: bit.ly/3DUGdvt

Happy Employee Appreciation Day to the incredible team at Palleon! Your dedication and passion drive our mission forward, making breakthroughs in #glycobiology possible. Thank you for all that you do. #TeamPalleon

Today is #IWD2025! We’re celebrating the women who are shaping #biotech, including our CSO, Li Peng, whose leadership in R&D drives our #cancer & #autoimmune pipelines. #DYK that she was a 2024 PharmaVoice 100 honoree? #WomenInSTEM

ICYMI: At AACR IO, Jessica Stark & Gabriel Rabinovich explored the emerging field of #glycoimmunology, highlighting the immunological role of glycans & the potential to target glyco-immune checkpoints in cancer treatment. Read about it here: bit.ly/4itjfgZ #AACRIO #glycotime

Happy Pi Day! 🥧 Like we needed an excuse to eat pie! We celebrated with a friendly pie baking competition—congratulations to our winners, Vijaya and Wayne! #TeamPalleon

Congrats to our Co-founder Carolyn Bertozzi for receiving the New England Biolabs Donald G. Comb Memorial Lectureship! The lectureship will take place at NEB HQ in Ipswich, MA, on March 27, 2025. Learn more here: prn.to/4i7l17V #glyotime

Palleon’s Co-founder Carolyn Bertozzi invented the field of bioorthogonal chemistry, earning her a Nobel Prize. She’s also a mentor, communicator, and champion of collaboration. Read more about her dynamic career: bit.ly/4hIPUyE #glycotime

We're proud to collaborate with Aideen Ryan from the Ollscoil na Gaillimhe | University of Galway! Her research in tumor immunology is uncovering new ways to harness the immune system to fight colon cancer. Read more about her work here: bit.ly/4htTWeF #glycotime

Our Co-founder, Carolyn Bertozzi, is speaking at the 2025 Stanford Medicine Drug Discovery Symposium (SDDS) next month! SDDS unites researchers, pharma, investors & more to share innovations shaping the future of medicine. Learn more: stan.md/3QhbO0g #glycotime #SDDS2025

A big step forward in autoimmune disease treatment! NMPA has given IND approval to Henlius for a Phase 2 trial of E-602 + rituximab HANLIKANG for #LupusNephritis. Read more: bit.ly/42Bh84H #glycotime

Big congrats to Hui Xu, Wayne Gatlin and Lizhi Cao on their promotions! 🎉 Your contributions to the Palleon team are so valued, and we’re excited for what’s ahead! #TeamPalleon

Cell surface sugars could unlock safer, more effective autoimmune treatments. Learn more in our Q&A with Li Peng, our CSO, on the science behind our lead drug candidate E-602, which will be evaluated in a Phase 2 trial for #lupusnephritis. bit.ly/4jnahm6 #glycotime

We took a culinary trip to Spain at Third Space Kitchen! 🇪🇸 Our team had a blast cooking (and eating!) together. 🥘 It’s events like these that make #TeamPalleon special.

Reminder: Our Co-founder, Carolyn Bertozzi, will be speaking at the 2025 Stanford Medicine Drug Discovery Symposium (SDDS) on April 29. She’ll join Session X: Discussion with Nobel Laureates, sharing insights on her career. Learn more: stan.md/3QhbO0g #glycotime #SDDS2025

Our CEO and Founder, Jim Broderick, CSO, Li Peng, and Scientific Co-Founder, Carolyn Bertozzi, participated in Henlius’s R&D Day in Shanghai this week! Great discussions on #autoimmunity and #oncology reinforced our strong collaboration. Excited for what’s ahead! #biotech

It’s the start of #NationalCancerResearchMonth! At Palleon, we’re exploring the role of glycans in #cancer and #immune dysfunction and are turning these findings into potential new therapies for patients. #glycotime #NCRM25

This month, an important conference is happening in Australia! #AUS-oMicS 2025 is a joint meeting with Australian Glycoscience Society, Australasian Proteomics Society, ANZ Metabolomics Society, and ANZSMS will highlight cutting-edge research in #glycoscience, proteomics & metabolomics. Learn more: bit.ly/4igjvR0

On #InternationalClinicalTrialsDay, we recognize the role clinical research plays in advancing new therapies. We're proud that our glyco-immunology approach will be evaluated in a Phase 2 trial for active #glomerulonephritis, evaluating E-602 (HLX79) + Henlius’s rituximab

Want to learn more about #glycobiology? Explore our Glycobiology Education Hub—featuring expert insights from leaders like our Scientific Co-Founder, Carolyn Bertozzi, key publications, and more. Discover more: bit.ly/4gQcAwQ